Business
Arcutis is a commercial-stage biopharmaceutical company focused on dermatology, with the ZORYVE product family across foam and cream versions.
Arcutis revenue rose 91.3% to $376.1M and losses narrowed sharply, but the forensic screen stayed cautious.
The read at a glance✓ Audited against SEC data
- Business mix — Commercial dermatology biopharmaNote
- Revenue — Revenue rose 91.3% to $376.1MOK
- Profitability — Net loss narrowed to $16.1MNote
- Cash — FCF improved to -$6.3MNote
- Balance sheet — Equity rose 20.3%OK
- Insiders — 0 buys / 58 sellsWatch
- Accounting — Altman-Z distress; Beneish flagWatch
Where the revenue comes from
Fiscal 2025, as Arcutis Biotherapeutics, Inc. reports it. History and quarterly detail are in the app.
- ZORYVE foam$181.9M
- ZORYVE cream 0.3%$121.0M
- ZORYVE cream 0.15%$68.3M
- ZORYVE cream 0.05%$911K
Leadership changes
From Arcutis Biotherapeutics, Inc.'s own filings, the day they're filed.
- Amit D. Munshi · director · appointmenteff. 2025-12-04
- David Topper · Chief Financial Officer · appointmenteff. 2024-04-10
- John Smither · Chief Financial Officer · appointmenteff. 2024-04-10
Latest filings
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-08-05
- 8-K · Company announcement2026-07-16
- 8-K · Company announcement2026-06-09
- 10-Q · Quarterly report2026-05-06
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Arcutis Biotherapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.